{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:06:16Z","timestamp":1770894376447,"version":"3.50.1"},"reference-count":13,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T00:00:00Z","timestamp":1514937600000},"content-version":"unspecified","delay-in-days":7491,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Acamprosate is a newly registered drug that appears to reduce alcohol-drinking in both animal models and clinical conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>In order to assess the efficacy and safety of the drug in the treatment of detoxified alcoholics, we performed a 90-day double-blind trial comparing two dosages of acamprosate (1332 mg\/day and 1998 mg\/day).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For all efficacy parameters, acamprosate appeared to be significantly superior to placebo, with a trend towards a better effect at the higher dosage. Furthermore, acamprosate appeared to be extremely safe.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study confirms that acamprosate could be an interesting adjuvant for maintaining abstinence in detoxified alcoholics.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.171.1.73","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T05:36:56Z","timestamp":1224049016000},"page":"73-77","source":"Crossref","is-referenced-by-count":135,"title":["Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients"],"prefix":"10.1192","volume":"171","author":[{"given":"I.","family":"Pelc","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Verbanck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. Le","family":"Bon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gavrilovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Lion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lehert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"S0007125000147233_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x"},{"key":"S0007125000147233_ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-3057(92)90210-7"},{"key":"S0007125000147233_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91682-7"},{"key":"S0007125000147233_ref11","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820110040006"},{"key":"S0007125000147233_ref13","first-page":"237","article-title":"Calciumdiacetylhomotaurinate (Ca-aota) decreases the action of excitatory amino acids in the rat neocortex in vitro","volume":"351","author":"Zeise","year":"1990","journal-title":"Progress in Clinical Biological Research"},{"key":"S0007125000147233_ref4","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.alcalc.a045093"},{"key":"S0007125000147233_ref6","volume-title":"ECDEU Assessment Manual for Psycho-pharmacology","author":"Guy","year":"1974"},{"key":"S0007125000147233_ref1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1987"},{"key":"S0007125000147233_ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1989.tb00406.x"},{"key":"S0007125000147233_ref5","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1988.49.149"},{"key":"S0007125000147233_ref8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"S0007125000147233_ref9","first-page":"157","article-title":"Review and discussion of statistical analysis of controlled clinical trials in alcoholism","volume":"suppl. 2","author":"Lehert","year":"1993","journal-title":"Alcohol and Alcoholism"},{"key":"S0007125000147233_ref10","first-page":"757","article-title":"The pharmacological treatment of alcoholism. From basic science to clinical medicine","volume":"30","author":"Verbanck","year":"1995","journal-title":"Alcohol and Alcoholism"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000147233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T20:46:05Z","timestamp":1557607565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000147233\/type\/journal_article"}},"subtitle":["A 90-day placebo-controlled dose-finding study"],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["S0007125000147233"],"URL":"https:\/\/doi.org\/10.1192\/bjp.171.1.73","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}